


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Canceled)

2. (Currently Amended) ~~The method according to claim 1~~ A method for treating pain in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of an I $\kappa$ B-kinase inhibitor of the compound of formula I; wherein the I $\kappa$ B-kinase inhibitor is a compound of formula I



or a stereoisomeric form thereof or a mixture of stereoisomeric forms in any ratio, or a physiologically tolerated salt thereof, wherein,

E is N, or a radical  $-C(R^{19})-$ , wherein,  $R^{19}$  is hydrogen or radical  $R^9$ , wherein,


$R^9$  is a characteristic radical of an amino acid,

aryl, wherein the aryl is optionally substituted,

heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted,

heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted, or

$-(C_1-C_6)$ -alkyl, wherein the alkyl is straight-chained or branched and is optionally substituted one, two or three times, independently of each other, by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein heteroaryl is optionally substituted, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted,  $-O-R^{11}$ ,  $=O$ , halogen,  $-CN$ ,  $-CF_3$ ,  $-S(O)_x-R^{11}$ , wherein x is zero, 1 or 2,  $-C(O)-O-R^{11}$ ,  $-C(O)-N(R^{11})_2$ ,  $-C(O)-R^{11}$ ,  $-N(R^{11})_2$ ,  $-(C_3-C_6)$ -cycloalkyl, a radical of formula




wherein,

R<sup>11</sup> is hydrogen,

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the alkyl is optionally substituted one, two or three times by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, halogen, -N-(C<sub>1</sub>-C<sub>6</sub>)<sub>n</sub>-alkyl, wherein n is zero, 1 or 2 and the alkyl is optionally substituted one, two or three times, independently of each other, by halogen or -C(O)-OH, -O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or -C(O)-OH, aryl, wherein aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, or heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, and wherein, the case of (R<sup>11</sup>)<sub>2</sub>, each R<sup>11</sup>, independently of each other, is hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein alkyl is optionally substituted one, two or three times by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, halogen, -N-(C<sub>1</sub>-C<sub>6</sub>)<sub>n</sub>-alkyl, wherein n is zero, 1 or 2 and the alkyl is optionally substituted one, two or three times, independently of each other, by halogen or -C(O)-OH, -O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or -C(O)-OH, aryl, wherein aryl is optionally substituted, or heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members;

at least one of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is, a radical of formula II,




wherein,

D is -C(O)-, -S(O)- or -S(O)<sub>2</sub>-;

R<sup>8</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

$R^9$  is a characteristic radical of an amino acid, aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted, or

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the alkyl is straight-chained or branched and is optionally substituted one, two or three times, independently of each other, by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein heteroaryl is optionally substituted, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted, -O-R<sup>11</sup>, =O, halogen, -CN, -CF<sub>3</sub>, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein x is zero, 1 or 2, -C(O)-O-R<sup>11</sup>, -C(O)-N(R<sup>11</sup>)<sub>2</sub>, -C(O)-R<sup>11</sup>, -N(R<sup>11</sup>)<sub>2</sub>, -(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, a radical of formula



wherein,

R<sup>11</sup> is hydrogen,


-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein alkyl is optionally substituted one, two or three times by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, halogen, -N-(C<sub>1</sub>-C<sub>6</sub>)<sub>n</sub>-alkyl, wherein n is zero, 1 or 2 and the alkyl is optionally substituted one, two or three times, independently of each other, by halogen or -C(O)-OH, -O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or -C(O)-OH, aryl, wherein aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, or heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, and

wherein, the case of (R<sup>11</sup>)<sub>2</sub>, each R<sup>11</sup>, independently of each other, is hydrogen,

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein alkyl is optionally substituted one, two or three times by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, halogen, -N-(C<sub>1</sub>-C<sub>6</sub>)<sub>n</sub>-alkyl, wherein n is zero, 1 or 2 and the alkyl is optionally substituted one, two or three times, independently of each other, by halogen or -C(O)-OH, -O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or -C(O)-OH, aryl, wherein aryl is optionally substituted, or heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members;

Z is aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted,  
-(C<sub>1</sub>-C<sub>6</sub>)-alkyl wherein the alkyl is optionally substituted,  
-C(O)-R<sup>11</sup>,  
-C(O)-O-R<sup>11</sup>,  
-C(O)-N(R<sup>11</sup>)<sub>2</sub>; or wherein, the radical of formula II, or

i) R<sup>8</sup> and R<sup>9</sup> form, together with the nitrogen and carbon to which they are bonded, a heterocyclic ring of formula IIa,



wherein,

D is -C(O)-, -S(O)- or -S(O)<sub>2</sub>-;

Z is aryl, wherein the aryl is optionally substituted,  
heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted,  
heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted,

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl wherein the alkyl is optionally substituted,  
-C(O)-R<sup>11</sup>,  
-C(O)-O-R<sup>11</sup>, or  
-C(O)-N(R<sup>11</sup>)<sub>2</sub>;

A is nitrogen or the radical -CH<sub>2</sub>-;

B is oxygen, sulfur, nitrogen or the radical -CH<sub>2</sub>-;

X is oxygen, sulfur, nitrogen or the radical  $-\text{CH}_2-$ ;

Y is selected from a bond, oxygen, sulfur, nitrogen, and radical  $-\text{CH}_2-$ , or


X and Y together form a phenyl, 1,2-diazine, 1,3-diazine, or 1,4-diazine radical, wherein,

the ring system formed by N, A, X, Y, B and carbon cannot contain more than one oxygen, X is cannot be oxygen, sulfur, or nitrogen when A is nitrogen, the ring system does not contain more than one sulfur atom, and contains 1, 2, 3 or 4 nitrogen, and, the oxygen and sulfur are not present simultaneously,

and wherein,

the ring system formed by N, A, X, Y, B and carbon is optionally substituted, one, two or three times, independently of each other, by  $-(\text{C}_1-\text{C}_8)\text{-alkyl}$ , wherein the alkyl is optionally substituted, one or two times, by  $-\text{OH}$ ,  $-(\text{C}_1-\text{C}_8)\text{-alkoxy}$ , halogen,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{CF}_3$ , methylenedioxy,  $-\text{C}(\text{O})$ ,  $-\text{C}(\text{O})\text{-CH}_3$ ,  $-(\text{C}_1-\text{C}_4)\text{-alkoxycarbonyl}$ ,  $-\text{CN}$ ,  $-\text{C}(\text{O})\text{-OH}$ ,  $-\text{C}(\text{O})\text{-NH}_2$ , tetrazolyl, phenyl, phenoxy, benzyl or benzyloxy; or

- ii)  $\text{R}^9$  and Z form, together with the carbon atoms to which they are in each case bonded, a heterocyclic ring of the formula IIc,



wherein,

D is  $-\text{C}(\text{O})-$ ,  $-\text{S}(\text{O})-$  or  $-\text{S}(\text{O})_2-$ ;

$\text{R}^8$  is hydrogen or  $-(\text{C}_1-\text{C}_4)\text{-alkyl}$ ;

$\text{R}^{11}$  is hydrogen,

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the alkyl is optionally substituted one, two or three times by aryl, wherein the aryl is optionally substituted, heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, halogen, -N-(C<sub>1</sub>-C<sub>6</sub>)<sub>n</sub>-alkyl, wherein n is zero, 1 or 2 and the alkyl is optionally substituted one, two or three times, independently of each other, by halogen or -C(O)-OH, -O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or -C(O)-OH,

aryl, wherein aryl is optionally substituted,

heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, or

heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members;

T is oxygen, sulfur, nitrogen or radical -CH<sub>2</sub>-;

W is oxygen, sulfur, nitrogen or the radical -CH<sub>2</sub>-;

V is selected from a bond, oxygen, sulfur, nitrogen or the radical -CH<sub>2</sub>-; or

T and V together form, or V and W together form a phenyl, 1,2-diazine, 1,3-diazine or 1,4-diazine radical, wherein, the ring system which is formed by N, T, V, W and two carbon atoms cannot contain more than one oxygen, cannot contain more than one sulfur and contains 1, 2, 3 or 4 nitrogen, wherein the oxygen and sulfur are not present simultaneously, and wherein,

the ring system which is formed by N, T, V, W and two carbon is optionally substituted, one, two three times, independently of each other, by -OH, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, -NO<sub>2</sub>, -NH<sub>2</sub>, -CF<sub>3</sub>, methylenedioxy, -C(O), -C(O)-CH<sub>3</sub>, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, -CN, -C(O)-OH, -C(O)-NH<sub>2</sub>, tetrazolyl, phenyl, phenoxy, benzyl or benzyloxy; and

wherein,

the remaining R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> in each case are, independently of each other selected from hydrogen, halogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl,

heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is  
optionally substituted,  
heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein the heterocycle is optionally substituted,  
-NO<sub>2</sub>,  
-CN,  
-O-(C<sub>0</sub>-C<sub>4</sub>)-alkylaryl,  
-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-OR<sup>11</sup>,  
-N(R<sup>11</sup>)<sub>2</sub>,  
-S(O)<sub>r</sub>-R<sup>11</sup>, wherein r is zero, 1 or 2, and  
-CF<sub>3</sub>;

R<sup>5</sup> is hydrogen, -OH or =O; and

R<sup>6</sup> is aryl, wherein aryl is optionally substituted,  
phenyl, wherein the phenyl is substituted one or two times by -CN, -NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-N(R<sup>11</sup>)<sub>2</sub>, -NH-C(O)-R<sup>11</sup>, -S(O)<sub>s</sub>-R<sup>11</sup>, wherein the s is zero, 1 or 2, -C(O)-R<sup>11</sup> or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl-NH<sub>2</sub>,

heteroaryl having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein, the heteroaryl is  
optionally substituted one, two, or three times, or  
heterocycle having 5, 6, 7, 8, 9, 10, 11, or 12 ring members, wherein, the heterocycle is optionally substituted one, two, or three times.

3. (Original) The method according to claim 2, wherein, for formula I, E is N, or a radical -C(R<sup>19</sup>)-, wherein, R<sup>19</sup> is hydrogen or radical R<sup>9</sup>, wherein, R<sup>9</sup> is a characteristic radical of an amino acid wherein the amino acid is derived from a naturally occurring  $\alpha$ -amino acids selected from alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid or aspartic acid, or



a characteristic radical of an amino acid wherein the radical is derived from an amino acid which is not naturally occurring selected from 2-aminoadipic acid, 2-aminobutyric acid, 2-aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminopropionic acid, 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 2-aminopimelic acid, 3-(2-thienyl)alanine, 3-(3-thienyl)alanine, sarcosine, pipecolic acid, 2-aminoheptanoic acid, hydroxylysine, N-methylisoleucine, 6-N-methyllysine, norleucine, N-methylvaline, norvaline, ornithine, alloseucine, 4-hydroxyproline, allohydroxylysine, allothreonine, 3-hydroxyproline, 3-(2-naphthyl)alanine, 3-(1-naphthyl)alanine), homocysteine, homophenylalanine, homocysteic acid, 2-amino-3-phenylaminoethylpropionic acid, 2-amino-3-phenylaminopropionic acid, homotryptophan, cysteic acid, 3-(2-pyridyl)alanine, 3-(3-pyridyl)alanine, 3-(4-pyridyl)alanine, phosphinothricin, 4-fluorophenylalanine, 3-fluorophenylalanine, 2-fluorophenylalanine, 4-chlorophenylalanine, 4-nitrophenylalanine, cyclohexylalanine, 4-aminophenylalanine, citrulline, 5-fluorotryptophan, 5-methoxytryptophan, methionine sulfone, methionine sulfoxide or  $-\text{NH}-\text{NR}^{11}-\text{CON}(\text{R}^{11})_2$ , wherein,

$\text{R}^{11}$  is hydrogen,

$-(\text{C}_1-\text{C}_6)$ -alkyl wherein, the alkyl is optionally substituted one, two, or three times by aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-\text{C}(\text{O})-(\text{C}_1-\text{C}_4)$ -alkyl,  $-\text{C}(\text{O})$ ,  $=\text{O}$ ,  $-\text{NH}-(\text{C}_1-\text{C}_4)$ -alkyl,  $-\text{NH}-((\text{C}_1-\text{C}_4)\text{-alkyl})_2$ ,  $-(\text{C}_1-\text{C}_8)$ -alkyl,  $-(\text{C}_1-\text{C}_8)$ -alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-\text{CF}_3$ , and hydroxy- $(\text{C}_1-\text{C}_4)$ -alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(\text{C}_1-\text{C}_4)$ -alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy,  $-\text{S}(\text{O})_x-\text{R}^{11}$  wherein x is zero, 1 or 2,  $-\text{O}-(\text{C}_1-\text{C}_4)$ -alkyl,  $-\text{C}(\text{O})-\text{OH}$ ,  $-\text{C}(\text{O})-\text{O}-(\text{C}_1-\text{C}_4)$ -alkyl,  $-\text{NH}-\text{C}(\text{O})-(\text{C}_1-\text{C}_4)$ -alkyl, and tetrazolyl, heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole,



benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone and triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)$ -alkyl,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)$ -alkyl,  $-NH-((C_1-C_4)$ -alkyl)<sub>2</sub>,  $-(C_1-C_8)$ -alkyl,  $-(C_1-C_8)$ -alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)$ -alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)$ -alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein x is zero, 1 or 2,  $-O-(C_1-C_4)$ -alkyl,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)$ -alkyl,  $-NH-C(O)-(C_1-C_4)$ -alkyl or tetrazolyl, halogen,  $-N-(C_1-C_6)_n$ -alkyl, wherein n is zero, 1 or 2 and alkyl is optionally substituted one, two or three times, independently of each other, by halogen or  $-C(O)-OH$ ,  $-O-(C_1-C_6)$ -alkyl, or  $-C(O)-OH$ ,

aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-

naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, and hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup> wherein x is zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, and tetrazolyl, or

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole, β-carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or

three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein  $x$  is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl, and

wherein, the case of  $(R^{11})_2$ , each  $R^{11}$ , independently of each other, is hydrogen,

$-(C_1-C_6)\text{-alkyl}$ , wherein alkyl is optionally substituted one, two or three times by aryl, selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$  wherein  $x$  is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$ , and tetrazolyl, heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrr-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine,

piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl, halogen,  $-N-(C_1-C_6)\text{-alkyl}$ , wherein n is zero, 1 or 2 and the alkyl is optionally substituted one, two, or three times, independently of each other, by halogen, or by  $-C(O)-OH$ ,  $-O-(C_1-C_6)\text{-alkyl}$ , or  $-C(O)-OH$ ,

aryl, wherein the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl and phenyl, and wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , and hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$  wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$ , or tetrazolyl, or

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine,

isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone and triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O), =O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein x is the integer zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl,

aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O), =O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$  wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$ , and tetrazolyl,

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-

dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline,


4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl,

$-(C_1-C_6)\text{-alkyl}$ , wherein the alkyl is straight-chain or branched and is optionally substituted one, two, or three times, independently of each other by aryl, selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$  wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$ , and tetrazolyl, heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine,



dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_xR^{11}$ , wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl,  $-(C_3-C_6)\text{-cycloalkyl}$ ,  $-O-R^{11}$ ,  $=O$ , halogen,  $-CN$ ,  $-CF_3$ ,  $-S(O)_xR^{11}$ , in which x is the integer zero, 1 or 2,  $-C(O)-O-R^{11}$ ,  $-C(O)-N(R^{11})_2$ ,

$-C(O)-R^{11}$ ,  $-N(R^{11})_2$ , a radical of the formula



, or a radical of the



wherein,

$R^{11}$  is hydrogen,

$-(C_1-C_6)\text{-alkyl}$  wherein, the alkyl is unsubstituted or substituted one, two, or three times by aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-



naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, and hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup> wherein x is zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or tetrazolyl, heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole, β-carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein x is the integer zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or tetrazolyl, halogen, -N-(C<sub>1</sub>-C<sub>6</sub>)<sub>n</sub>-alkyl, in which n is zero, 1 or 2 and alkyl is optionally substituted one, two or three times,

independently of each other, by halogen or -C(O)-OH, -O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or -C(O)-OH, or

aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl and phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, and hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup> wherein x is zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and tetrazolyl, or

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole, β-carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein  $x$  is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)\text{-OH}$ ,  $-C(O)\text{-O-}(C_1-C_4)\text{-alkyl}$ ,  $-NH\text{-C(O)\text{-}(C_1-C_4)\text{-alkyl}}$  or tetrazolyl,

wherein, the case of  $(R^{11})_2$ , each  $R^{11}$ , independently of each other, is hydrogen,

$-(C_1-C_6)\text{-alkyl}$  wherein, the alkyl is optionally substituted one, two, or three times by aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl or phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-C(O)\text{-}(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH\text{-}(C_1-C_4)\text{-alkyl}$ ,  $-NH\text{-}((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , and hydroxy- $-(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$  wherein  $x$  is zero, 1 or 2,  $-O\text{-}(C_1-C_4)\text{-alkyl}$ ,  $-C(O)\text{-OH}$ ,  $-C(O)\text{-O-}(C_1-C_4)\text{-alkyl}$ ,  $-NH\text{-C(O)\text{-}(C_1-C_4)\text{-alkyl}}$ , or tetrazolyl, heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole,

pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone and triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein x is the integer zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl, halogen,  $-N-(C_1-C_6)_n\text{-alkyl}$ , in which n is zero, 1 or 2 and alkyl is optionally substituted one, two or three times, independently of each other, by halogen or  $-C(O)-OH$ , or  $-O-(C_1-C_6)\text{-alkyl}$ , or  $-C(O)-OH$ , or

aryl, wherein, the aryl is selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl or phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)$ ,  $=O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , and hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$  wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$ , or tetrazolyl, and

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran,

benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone and triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from  $-C(O)-(C_1-C_4)\text{-alkyl}$ ,  $-C(O), =O$ ,  $-NH-(C_1-C_4)\text{-alkyl}$ ,  $-NH-((C_1-C_4)\text{-alkyl})_2$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl,  $-CF_3$ , hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  $-(C_1-C_4)\text{-alkoxycarbonyl}$ , phenyl, phenoxy, benzyl, benzyloxy,  $-S(O)_x-R^{11}$ , wherein x is zero, 1 or 2,  $-O-(C_1-C_4)\text{-alkyl}$ ,  $-C(O)-OH$ ,  $-C(O)-O-(C_1-C_4)\text{-alkyl}$ ,  $-NH-C(O)-(C_1-C_4)\text{-alkyl}$  or tetrazolyl;

at least one of one of  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  is a radical of the formula II, wherein,

D is  $-C(O)-$ ,  $-S(O)-$  or  $-S(O)_2-$ ;

$R^8$  is hydrogen atom or  $(C_1-C_4)\text{-alkyl}$ ;

Z is aryl, selected from anthryl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, fluorenyl, naphthyl, 1-naphthyl, 2-naphthyl or phenyl, wherein the aryl is optionally substituted one, two or three times independently of one another by a radical selected from

-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl,  
hydroxyl, -CF<sub>3</sub>, and hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy,  
formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-  
alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup> wherein x is  
zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-  
(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or tetrazolyl, or

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the  
heteroaryl is optionally substituted and derived from azepine, azetidine,  
benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene,  
2-benzothiophene, 2-benzoxazole, β-carboline, quinoxaline, quinazoline,  
quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine,  
3-hydroxypyrr-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline,  
indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole,  
2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-  
methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole,  
oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-  
oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-  
isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine,  
piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine,  
pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine,  
pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole,  
thiazole, thiomorpholine, thiophene, triazole, triazolone and triazole, wherein,  
the heteroaryl is optionally substituted one, two or three times by a radical  
derived from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-  
C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino,  
trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy,  
ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-  
C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein  
x is the integer zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-  
alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or tetrazolyl, or -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the



alkyl is straight-chain or branched and is substituted one or two times by phenyl or -OH, -C(O)-O-R<sup>11</sup>, or -C(O)-N(R<sup>11</sup>)<sub>2</sub>, and wherein,

the remaining R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> in each case are, independently of each other selected from

hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole,  $\beta$ -carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone and triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein x is the integer zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or tetrazolyl, or

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,

-NO<sub>2</sub>,

-CN,

-O-(C<sub>0</sub>-C<sub>4</sub>)-alkylaryl,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,



-OR<sup>11</sup>,  
-N(R<sup>11</sup>)<sub>2</sub>,  
-S(O)<sub>x</sub>-R<sup>11</sup>, wherein x is zero, 1 or 2, and  
-CF<sub>3</sub>;

R<sup>5</sup> is hydrogen, -OH or =O; and

R<sup>6</sup> is aryl, selected from naphthyl, 1-naphthyl, 2-naphthyl, phenyl, biphenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, anthryl and fluorenyl, wherein, the aryl is optionally substituted, one, two or three times, by the radical chosen from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, in which x is zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and tetrazolyl, or

heteroaryl, having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, wherein the heteroaryl is optionally substituted and derived from azepine, azetidine, benzimidazole, benzodioxolane, 2-benzofuran, benzothiazole, benzothiophene, 2-benzothiophene, 2-benzoxazole, β-carboline, quinoxaline, quinazoline, quinoline, 2-quinoxaline, cyclohepta[b]-5-pyrrole, diazepine, dihydropyridine, 3-hydroxypyrro-2,4-dione, imidazole, 4-imidazole, imidazolidine, imidazoline, indazole, indole, isoquinoline, isoindole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, methylimidazole, 3-(N-methylpyrrolidine), morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, 1,2,3,5-oxathiadiazole-2-oxide, 1-oxo-1,2-dihydro-3-isoquinol, phenylpyrrole, 5-phenyl-2-pyrrole, phthalazine, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyrazoline, pyridazine, pyrimidine, pyridine, pyridyl-N-oxide, 2-pyrrole, 3-pyrrole, pyrrolidine, pyrroline, 4,5,6,7-tetrahydro-2-indole, tetrahydrothienyl, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, triazole, triazolone or triazole, wherein, the heteroaryl is optionally substituted one, two or three times by a radical derived from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -

C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein x zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or tetrazolyl.

4. (Currently Amended) The method according to claim 2, wherein, for formula I,

E is N or the radical -C(R<sup>19</sup>)-, wherein R<sup>19</sup> is hydrogen;

at least one of one of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is a radical of the formula II, wherein,

R<sup>8</sup> is hydrogen;

R<sup>9</sup> is a characteristic radical of an amino acid wherein, the amino acid is selected from histidine, serine, tryptophan, threonine, cysteine, methionine, asparagine, glutamine, lysine, arginine, glutamic acid and aspartic acid, or  
-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein alkyl is straight-chain or branched and is optionally substituted, one or two times, by phenyl, a radical selected from azepine, azetidine, benzimidazole, benzothiazole, benzothiophene, benzoxazole, diazepine, imidazole, indole, isothiazole, isoxazole, morpholine, 1,3,4-oxadiazole, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, oxazole piperidine, pyrazine, pyrazole, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrroline, thiazole, thiomorpholine, thiophene and triazole, -NH(R<sup>11</sup>), -C(O)-R<sup>12</sup>, wherein R<sup>12</sup> is naphthyl, phenyl, morpholinyl or pyrimidinyl, -O-R<sup>11</sup>, -N(R<sup>12</sup>)-phenyl, wherein R<sup>12</sup> is naphthyl, phenyl, morpholinyl or pyrimidinyl, -S(O)<sub>x</sub>-R<sup>12</sup>, in which x is zero, 1 or 2, -CN, or -(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl,  
wherein,

the phenyl radical, the radical selected from azepine, azetidine, benzimidazole, benzothiazole, benzothiophene, benzoxazole, diazepine, imidazole, indole, isothiazole, isoxazole, morpholine, 1,3,4-oxadiazole, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, oxazole piperidine, pyrazine, pyrazole, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrroline, thiazole, thiomorpholine, thiophene and

triazole, the  $-C(O)-R^{12}$ , wherein  $R^{12}$  is naphthyl, phenyl, morpholinyl or pyrimidinyl, the  $-(C_3-C_6)$ -cycloalkyl and the  $R^{12}$  are optionally substituted, one or two times, by  $-OH$ ,  $-(C_1-C_4)$ -alkyl,  $-CF_3$ , halogen,  $-O-(C_1-C_4)$ -alkyl,  $-COOH$ ,  $-C(O)-O-(C_1-C_4)$ -alkyl,  $-NH_2$  or  $-NH-C(O)-(C_1-C_4)$ -alkyl,

and wherein,

$R^{11}$  is  $-(C_1-C_4)$ -alkyl,  $R^{13}$  or  $-N(R^{13})_2$ , wherein the  $R^{13}$ , independently of each other, are selected from hydrogen,  $-(C_1-C_6)$ -alkyl,  $-(C_1-C_4)$ -alkyl- $O-(C_1-C_4)$ -alkyl,  $-(C_1-C_6)$ -alkyl- $N(R^{15})_2$ , wherein  $R^{15}$  is  $R^{15}$  is hydrogen atom or  $-(C_1-C_4)$ -alkyl,  $-(C_0-C_4)$ -alkyl, wherein the alkyl is substituted one or two time, by imidazolyl, morpholinyl or phenyl;

Z is a heteroaryl radical selected from 3-hydroxypyrrro-2,4-dione, imidazole, imidazolidine, imidazoline, indazole, isothiazole, isothiazolidine, isoxazole, isoxazolidine, 2-isoxazolidine, isoxazolone, morpholine, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 1,2,3,5-oxathiadiazole-2-oxide, oxazole, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, piperazine, pyrazine, pyrazole, pyrazolidine, pyrazoline, pyridazine, pyrimidine, tetrazole, thiadiazole, thiazole, thiomorpholine, triazole and triazolone, wherein the heteroaryl radical is optionally substituted, one, two or three times, independently of each other, by  $-C(O)-R^{15}$ , wherein  $R^{15}$  is hydrogen or  $-(C_1-C_4)$ -alkyl,  $-(C_1-C_4)$ -alkyl,  $-O-R^{15}$ , wherein,  $R^{15}$  is hydrogen or  $-(C_1-C_4)$ -alkyl,  $-N(R^{15})-R^{16}$ , wherein, wherein  $R^{15}$  and  $R^{16}$  are, independent of each other, hydrogen or  $-(C_1-C_4)$ -alkyl, halogen, or a keto radical,  $-C(O)-R^{15}$ , wherein  $R^{15}$  is hydrogen atom or  $-(C_1-C_4)$ -alkyl,  $-C(O)-R^{15}$ , wherein  $R^{15}$  is hydrogen atom or  $-(C_1-C_4)$ -alkyl, or  $-C(O)-N(R^{15})R^{16}$ , wherein  $R^{15}$  and  $R^{16}$  are, independent of each other, hydrogen or  $-(C_1-C_4)$ -alkyl;

- i)  $R^8$  and  $R^9$  form, together with the nitrogen atom and carbon atom to which they are in each case bonded, a ring of the formula IIa from the group pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, piperylene, pyridazine, pyrimidine, pyrazine, piperazine, pyrazole, imidazole, pyrazoline, imidazoline, pyrazolidine, imidazolidine, oxazole, isoxazole, 2-isoxazolidine, isoxazolidine,

morpholine, isothiazole, thiazole, tetrazole, 1,2,3,5-oxathiadiazole-2-oxides, oxadiazolone, isoxazolone, triazolones, oxadiazolidinedione, triazole, which are substituted by F, CN, CF<sub>3</sub> or COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, 3-hydroxypyrro-2,4-diones, 5-oxo-1,2,4-thiadiazoles, 1,3,4-oxadiazole, isothiazolidine, thiomorpholine, indazole, thiadiazole, benzimidazole, quinoline, triazole, phthalazine, quinazoline, quinoxaline, purine, pteridine, indole, tetrahydroquinoline, tetrahydroisoquinoline and isoquinoline; or

- ii) R<sup>9</sup> and Z form, together with the carbon atoms to which they are in each case bonded, a ring of the formula IIc from the group pyrrole, pyrroline, pyrrolidine, pyridine, piperidine, piperylene, pyridazine, pyrimidine, pyrazine, piperazine, pyrazole, imidazole, pyrazoline, imidazoline, pyrazolidine, imidazolidine, oxazole, isoxazole, 2-isoxazolidine, isoxazolidine, morpholine, isothiazole, thiazole, isothiazolidine, thiomorpholine, indazole, thiadiazole, benzimidazole, quinoline, triazole, phthalazine, quinazoline, quinoxaline, purine, pteridine, indole, tetrahydroquinoline, tetrahydroisoquinoline, isoquinoline, tetrazole, 1,2,3,5-oxathiadiazole-2-oxides, oxadiazolone, isoxazolone, triazolones, oxadiazolidinedione, triazole, which are substituted by F, CN, CF<sub>3</sub> or COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, 3-hydroxypyrro-2,4-diones, 1,3,4-oxadiazole or 5-oxo-1,2,4-thiadiazole; and

wherein,

the remaining R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> in each case are, independently of each other selected from

hydrogen,  
halogen,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-CN,  
-NO<sub>2</sub>,  
-O-(C<sub>0</sub>-C<sub>4</sub>)-alkyl-phenyl,  
-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-N-(C<sub>0</sub>-C<sub>4</sub>)-alkyl-phenyl,  
-N-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and  
-CF<sub>3</sub>;

$R^5$  is hydrogen, -OH, or =O; and

$R^6$  is phenyl, substituted one or two times by -CN, -NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or -NH<sub>2</sub>, or pyridine or pyrimidine, wherein pyridine or pyrimidine is optionally substituted, one, two or three times by a radical selected from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein x is zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and tetrazolyl.

5. (Original) The method according to claim 2, wherein, for formula I,

E is a radical -C(R<sup>19</sup>)-, wherein, R<sup>19</sup> is hydrogen or R<sup>9</sup>, wherein,

R<sup>9</sup> is -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is straight-chain or branched and is substituted one or two times, independently of each other, by -S(O)-R<sup>11</sup>, wherein, R<sup>11</sup> is hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein alkyl is optionally substituted, one, two or three times, independently of each other by halogen, or phenyl, wherein, the phenyl is optionally substituted, one, two, or three times, independently of each other, by halogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -N(R<sup>11</sup>)<sub>2</sub>, wherein, R<sup>11</sup> is hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein alkyl is optionally substituted, one, two or three times, independently of each other by halogen, or phenyl, wherein phenyl is optionally substituted, one, two, or three times, independently of each other, by halogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or pyrrole, or

a characteristic radical of an amino acid selected from the histidine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, arginine, glutamic acid and aspartic acid;

at least one of one of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is a radical of the formula II, wherein, for formula II,

D is -C(O)-;

R<sup>8</sup> is hydrogen;

Z is 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, -C(O)-OH or -C(O)-NH<sub>2</sub>;

R<sup>11</sup> is hydrogen,


-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the alkyl is optionally substituted, one, two or three times,  
independently of each other by halogen, or  
phenyl, wherein phenyl is optionally substituted; one, two, or three times,  
independently of each other, by halogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

the remaining R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are in each case hydrogen;

R<sup>5</sup> is hydrogen atom, and

R<sup>6</sup> is phenyl, pyridine or pyrimidine, wherein the phenyl, pyridine or pyrimidine is  
optionally substituted, one, two or three times, by a radical selected from -C(O)-(C<sub>1</sub>-C<sub>4</sub>)-  
alkyl, -C(O), =O, -NH-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-((C<sub>1</sub>-C<sub>4</sub>)-alkyl)<sub>2</sub>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-  
alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, -CF<sub>3</sub>, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, -S(O)<sub>x</sub>-R<sup>11</sup>, wherein x is  
zero, 1 or 2, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -C(O)-OH, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl  
and tetrazolyl.

6. (Original) The method according to claim 2, wherein, for formula Ia,



or a stereoisomeric form thereof or a mixture of stereoisomeric forms in any ratio, or a physiologically tolerated salt thereof, wherein,

E is N or CH;

M is N or CH;

R21 is hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-CN,

 $-\text{CF}_3,$ 

-OR<sup>15</sup>, wherein, R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-N(R<sup>15</sup>)-R<sup>16</sup> wherein, R<sup>15</sup> and R<sup>16</sup> are, independently of each other, hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

**-C(O)-R<sup>15</sup>**, wherein, R<sup>15</sup> is hydrogen or **-(C<sub>1</sub>-C<sub>4</sub>)-alkyl**, or

-S(O)<sub>x</sub>-R<sup>15</sup>, wherein, x is zero, 1 or 2, and R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R31 is hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-CN,

 $-\text{CF}_3$ 

-OR<sup>15</sup>, wherein, R<sup>15</sup> is hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-N(R<sup>15</sup>)-R<sup>16</sup> wherein, R<sup>15</sup> and R<sup>16</sup> are, independently of each other, hydrogen or



-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-R<sup>15</sup>, whereiu, R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or

-S(O)<sub>x</sub>-R<sup>15</sup>, wherein, x is zero, 1 or 2, and R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R22 is a heteroaryl radical selected from 3-hydroxypyrro-2,4-dione, imidazole, imidazolidine, imidazoline, indazole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 1,2,3,5-oxathiadiazole-2-oxide, 5-oxo-4,5-dihydro-[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, piperazine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyrimidine, tetrazole, thiadiazole, thiazole, thiomorpholine, triazole and triazolone, wherein the heteroaryl radical is optionally substituted one, two or three times by -C(O)-R<sup>15</sup>, wherein R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -O-R<sup>15</sup>, wherein R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -N(R<sup>15</sup>)-R<sup>16</sup>, wherein R<sup>15</sup> and R<sup>16</sup> are, independently of each other, hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, halogen, or a keto radical,

-C(O)-R<sup>15</sup>, wherein R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-OR<sup>15</sup>, wherein R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or

-C(O)-N(R<sup>17</sup>)-R<sup>18</sup>, wherein R<sup>17</sup> and R<sup>18</sup> are, independently of each other, hydrogen, -(C<sub>1</sub>-C<sub>4</sub>)-

alkyl-OH, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R23 is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl; and

R24 is a heteroaryl radical selected from pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, tetrazole, 1,2,3,5-oxathiadiazole-2-oxide, triazolones, oxadiazolones, isoxazolones, oxadiazolidinedione, triazole, 3-hydroxypyrro-2,4-dione, 5-oxo-1,2,4-thiadiazole, pyridine, pyrazine, pyrimidine, indole, isoindole, indazole, phthalazine, quinoline, isoquinoline, quinoxaline, quinazoline, cinnoline, β-carboline and benzo fused cyclopenta derivatives or cyclohexa derivatives of these heteroaryl radicals, wherein the heteroaryl radical is optionally substituted, one, two or three times, independently of each other, by -(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -(C<sub>1</sub>-C<sub>5</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl or

-(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, or an aryl radical selected from phenyl, naphthyl, 1-naphthyl, 2-naphthyl, biphenyl, 2-biphenyl, 3-biphenyl and 4-biphenyl, anthryl and fluorenyl, wherein the aryl radical is optionally substituted, one, two or three times, independently of each other, by -(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -(C<sub>1</sub>-C<sub>5</sub>)-alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl or -(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl.

7. (Original) The method according to claim 6, wherein, for formula Ia,

E is N or CH;

M is N or CH;

R<sub>21</sub> is hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-CN,

-CF<sub>3</sub>,

-OR<sup>15</sup>, wherein, R<sup>15</sup> is hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-N(R<sup>15</sup>)-R<sup>16</sup> wherein, R<sup>15</sup> and R<sup>16</sup> are, independently of each other, hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-R<sup>15</sup>, wherein, R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or

-S(O)<sub>x</sub>-R<sup>15</sup>, wherein, x is zero, 1 or 2, and R<sup>15</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R<sub>22</sub> is a heteroaryl radical selected from imidazole, isothiazole, isoxazole, 2-isoxazolidine,

isoxazolidine, isoxazolone, 1,3,4-oxadiazole, oxadiazolidinedione, 1,2,3,5-

oxadiazolone, oxazole, 5-oxo-4,5-dihydro[1,3,4]oxadiazole, tetrazole,

thiadiazole, thiazole, triazole and triazolone, wherein the heteroaryl radical is

optionally substituted one, two or three times by a keto radical, halogen, or

-(C<sub>1</sub>-C<sub>2</sub>)-alkyl,

-C(O)-N(R<sup>17</sup>)-R<sup>18</sup>, wherein R<sup>17</sup> and R<sup>18</sup> are hydrogen, -(C<sub>1</sub>-C<sub>2</sub>)-alkyl-OH, -O-(C<sub>1</sub>-C<sub>2</sub>)-alkyl, or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R23 is hydrogen, methyl or ethyl;

R24 is a heteroaryl radical selected from unsaturated, partially saturated and completely saturated rings which are derived from pyridine, pyrazine, pyrimidine, pyridazine, pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, triazole or isothiazole, wherein the heteroaryl radical is optionally substituted, one, two or three times, independently of each other by  $-(C_1-C_4)$ -alkyl,  $-(C_1-C_4)$ -alkoxy, F, Cl, I, Br, nitro; amino, trifluoromethyl, hydroxyl, hydroxy- $-(C_1-C_4)$ -alkyl, methylenedioxy, ethylenedioxy, formyl, aceryl, cyano, hydroxycarbonyl, aminocarbonyl or  $-(C_1-C_4)$ -alkoxycarbonyl, or phenyl, wherein, the phenyl is optionally substituted one, two or three times, independently of each other, by F, Cl, I, Br,  $CF_3$ ,  $-OH$ ,  $-(C_1-C_4)$ -alkyl or  $-(C_1-C_4)$ -alkoxy; and

R31 is hydrogen,

halogen,

$-(C_1-C_4)$ -alkyl,

$-CN$ ,

$-CF_3$ ,

$-OR^{15}$ , wherein,  $R^{15}$  is hydrogen atom or  $-(C_1-C_4)$ -alkyl,

$-N(R^{15})-R^{16}$  wherein,  $R^{15}$  and  $R^{16}$  are, independently of each other, hydrogen or  $-(C_1-C_4)$ -alkyl,

$-C(O)-R^{15}$ , wherein,  $R^{15}$  is hydrogen or  $-(C_1-C_4)$ -alkyl, or

$-S(O)_x-R^{15}$ , wherein,  $x$  is zero, 1 or 2, and  $R^{15}$  is hydrogen or  $-(C_1-C_4)$ -alkyl.

8. (Original) The method according to claim 2, wherein the compound of formula I is N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide or N-((S)-1-carbamoyl-2-diphenylaminoethyl)-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide.

9. (Original) The method according to claim 2, wherein the compound of formula Ia is N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide or N-((S)-1-carbamoyl-2-diphenylaminoethyl)-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide.
10. (Original) The method according to claim 6, wherein the compound of formula I is N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide or N-((S)-1-carbamoyl-2-diphenylaminoethyl)-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide.
11. (Original) The method according to claim 6, wherein the compound of formula Ia is, wherein the compound N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide or N-((S)-1-carbamoyl-2-diphenylaminoethyl)-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide.
12. (Currently Amended) ~~A The method of claim 2 wherein the pain is chronic or acute for producing a pharmaceutical for the prophylaxis and therapy of acute pain or chronic pain, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of a compound according to claim 1.~~
13. (Currently Amended) The method according to claim ~~11~~ 12, wherein the chronic pain is a chronic pain selected from chronic musculoskeletal diseases, a pain associated with menstruation, a pain associated with osteoarthritis or rheumatoid arthritis, a pain associated with intestinal inflammation, a pain associated with cardiac muscle inflammation, a pain associated with multiple sclerosis, a pain associated with neuritis, a pain associated with a carcinoma and a sarcoma, a pain associated with AIDS, a pain associated with chemotherapy, an amputation pain, a trigeminus neuralgia, a headache, and a neuropathic pain.

14. (Currently Amended) The method according to claim ~~11~~ 12, wherein the acute pain is an acute pain selected from a pain following injury, a post-operative pain, a pain associated with an acute attack of gout, and an acute pain following jaw-bone surgical intervention.
15. (Canceled)
16. (Currently Amended) The method according to claim ~~12~~ 13 wherein the headache is a migraine cephalalgia.
17. (Currently Amended) The method according to claim ~~12~~ 13 wherein the neuropathic pain is post-herpes zoster neuralgia.